Hunt Companies Finance Trust Inc
Change company Symbol lookup
Select an option...
HCFT Hunt Companies Finance Trust Inc
BHV BlackRock Virginia Municipal Bond Trust
JNJ Johnson & Johnson
TRQ Turquoise Hill Resources Ltd
STAA STAAR Surgical Co
PRPL Purple Innovation Inc
INTC Intel Corp
PSB PS Business Parks Inc
GWRE Guidewire Software Inc
UYM.TC ProShares Ultra Basic Materials ETF
Go

Financials : Mortgage Real Estate Investment Trusts (REITs) | Small Cap Value
Company profile

Hunt Companies Finance Trust, Inc., formerly Five Oaks Investment Corp., is a real estate specialty finance company. The Company is focused on investing in a portfolio of mortgage-backed securities (MBS), mortgage loans and other real estate related investments. It is engaged in various real estate businesses, including multifamily ownership, non-bank agency lending, loan servicing, property management, construction, development and military housing. It offers a suite of products, including floating-rate transitional loans, fixed rate commercial real estate loans, mezzanine and preferred financing. It also provides Fannie, Freddie and federal housing administration (FHA) loans for multifamily, student housing, seniors, healthcare and manufactured housing. The Company is externally managed by Hunt Investment Management, LLC.

Closing Price
$2.81
Day's Change
0.02 (0.72%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.83
Day's Low
2.79
Volume
(Light)
Volume:
13,634

10-day average volume:
20,892
13,634

Group of 9 drug company CEOs pledge to make sure COVID-19 vaccine follows full regulatory path

6:44 am ET September 8, 2020 (MarketWatch)
Print

A group of nine drug company chief executives said Tuesday they have signed a pledge to make the safety and well-being of vaccinated individuals the top priority in developing the first COVID-19 vaccine. The CEOs of AstraZeneca PLC (AZN.LN), BioNTech SE(BNTX), GlaxoSmithKline PLC (GSK.LN), Johnson & Johnson (JNJ), Merck & Co. Inc. (MRK), Moderna Inc. (MRNA), Novavax Inc. (NVAX), Pfizer Inc. (PFE) and Sanofi SA (SAN.FR), signed the pledge to demonstrate their unified commitment to upholding the integrity of the scientific process as they work to develop a vaccine that can win regulatory approval. "We, the undersigned biopharmaceutical companies, want to make clear our on-going commitment to developing and testing potential vaccines for COVID-19 in accordance with high ethical standards and sound scientific principles," said the pledge. That means following all the steps that a regulator like the U.S. Food and Drug Administration deems essential in approving a vaccine, including large, high quality clinical trials that are randomized and observer-blinded and involve a diverse group of participants. The companies will only submit for approval a vaccine that has demonstrated safety and efficacy via a Phase 3 clinical study designed and conducted to meet all regulatory requirements, it said. "We believe this pledge will help ensure public confidence in the rigorous scientific and regulatory process by which COVID-19 vaccines are evaluated and may ultimately be approved," the CEOs wrote. The pledge comes amid concern the Trump administration may try to rush out a vaccine ahead of the November election, after the CDC directed state governors to have vaccine distribution centers set up by Nov. 1. It also comes after Russia registered a vaccine before completing Phase 3 trials, that it plans to start administering to health care and other front line workers in October.

-Ciara Linnane; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

September 08, 2020 06:44 ET (10:44 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.